<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081133</url>
  </required_header>
  <id_info>
    <org_study_id>03-126</org_study_id>
    <secondary_id>CDR0000358923</secondary_id>
    <nct_id>NCT00081133</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous Leukemia in Accelerated or Blastic Phase Disease or Ph+ Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to&#xD;
      stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the&#xD;
      growth of cancer cells by blocking the enzymes necessary for their growth. Combining arsenic&#xD;
      trioxide with imatinib mesylate may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of arsenic trioxide&#xD;
      when given with imatinib mesylate and to see how well they work in treating patients with&#xD;
      accelerated phase or blastic phase chronic myelogenous leukemia or Philadelphia&#xD;
      chromosome-positive acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolererated dose of arsenic trioxide when administered with&#xD;
           imatinib mesylate in patients with accelerated or blastic phase chronic myelogenous&#xD;
           leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.&#xD;
&#xD;
        -  Determine the rate of complete morphologic remission in the bone marrow of patients&#xD;
           treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study of arsenic trioxide followed by a phase II&#xD;
      study.&#xD;
&#xD;
        -  Phase I:&#xD;
&#xD;
             -  Induction therapy: Patients receive oral imatinib mesylate once daily on days 1-35&#xD;
                (weeks 1-5) and arsenic trioxide IV over 1-4 hours on days 1-5, 8-12, 15-19, and&#xD;
                22-26 (weeks 1-4).&#xD;
&#xD;
      Patients undergo bone marrow evaluation on week 5. Patients achieving a morphologic remission&#xD;
      proceed to consolidation therapy. Patients not achieving morphologic remission receive a&#xD;
      second course of imatinib mesylate as above on weeks 6-10 and arsenic trioxide as above on&#xD;
      weeks 6-9. Patients are re-evaluated on week 10. Patients achieving morphologic remission&#xD;
      proceed to consolidation therapy. Patients not achieving a morphologic remission are removed&#xD;
      from study.&#xD;
&#xD;
        -  Consolidation therapy: Patients receive oral imatinib mesylate as in induction therapy&#xD;
           on approximately weeks 6-11 (or weeks 11-16*) and arsenic trioxide IV over 1-4 hours on&#xD;
           days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (approximately weeks 6-9 OR weeks&#xD;
           11-14*).&#xD;
&#xD;
      Patients who remain in morphologic remission receive a second course of imatinib mesylate as&#xD;
      in induction therapy on approximately weeks 12-17 (or weeks 17-22*) and arsenic trioxide as&#xD;
      above (in consolidation therapy) on approximately weeks 12-15 (or weeks 17-20*).&#xD;
&#xD;
      NOTE: *For patients who receive a second course of induction therapy&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of arsenic trioxide until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive arsenic trioxide at the MTD and imatinib mesylate as in phase&#xD;
           I.&#xD;
&#xD;
      Treatment in both phases continues in the absence of unacceptable toxicity or disease&#xD;
      progression.&#xD;
&#xD;
      After completion of consolidation therapy, patients may continue imatinib mesylate off study&#xD;
      at the discretion of the physician. Patients who become candidates for stem cell&#xD;
      transplantation at any time during the study are removed from study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-43 patients (6-12 for phase I and 37 [including 6 patients&#xD;
      from phase I] for phase II) will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) in one of the following phases:&#xD;
&#xD;
                    -  Blastic phase*&#xD;
&#xD;
                    -  Accelerated phase*&#xD;
&#xD;
                         -  No appropriate donors for stem cell transplantation NOTE: *Must have&#xD;
                            received high-dose (600-800 mg/day) imatinib mesylate of no more than 3&#xD;
                            months duration&#xD;
&#xD;
               -  Acute lymphoblastic leukemia&#xD;
&#xD;
                    -  Philadelphia chromosome positive by cytogenetic confirmation&#xD;
&#xD;
                         -  Patients with only bcr-abl-positive disease by polymerase chain&#xD;
                            reaction are not eligible&#xD;
&#xD;
                    -  &gt; 10% blasts in the bone marrow&#xD;
&#xD;
          -  No isolated extramedullary disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 2 times ULN&#xD;
&#xD;
          -  INR and PTT ≤ 1.5 times ULN (except for patients on anticoagulation therapy)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Baseline QTc intervals &lt; 480 ms&#xD;
&#xD;
          -  No chronic arrhythmias&#xD;
&#xD;
          -  No active coronary artery disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No chronic electrolyte abnormalities&#xD;
&#xD;
          -  No prior non-compliance to medical regimens&#xD;
&#xD;
          -  No patients who are considered potentially unreliable&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  No other active malignancies except superficial epithelial cancers&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for at least 3&#xD;
             months after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior peripheral blood stem cell or bone marrow transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior hydroxyurea allowed&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior anagrelide allowed&#xD;
&#xD;
          -  No concurrent warfarin for therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent low molecular weight heparin is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellin Berman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>untreated adult acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

